M. John Gill, MB, ChB, MSc

Professor
University of Calgary
Calgary, AB, Canada

Disclosure: Gilead: Board Member
Merck: Board Member
Viiv: Board Member

Presentation(s):

• LB9 - The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care

  Friday, October 4
  1:55 PM – 2:05 PM